96.88
-0.22%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai Haoyuan Chemexpress Co
Its shares trade on Shanghai under the ticker 688131.SS. It has been listed since 8 June 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.87bn and net income of CN¥247.8m. At that date it held total assets of CN¥6.29bn and shareholders' equity of CN¥3.13bn.
Shanghai Haoyuan Chemexpress Co. Ltd. engages in the research and development of related compounds in the development of new drugs. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-06-08. The firm's main products include molecular building blocks and tool compounds. The firm's products also include active pharmaceutical ingredients (APIs) and intermediates. The firm also provides related services such as contract research organization (CRO) service. The firm's molecular building blocks and tool compounds are applied in all stages of the drug discovery process. The firm distributes its products in domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 8 Jun 2021
- Employees
- 3,368
- Website
- chemexpress.com.cn ↗
Leadership
Pay as last reported
- Mr. Baofu ZhengChairman of the Board, General Manager, since 2015CN¥779,500
- Ms. Min LiChief Financial OfficerCN¥630,500
- Mr. Shuoliang LiChief Scientific Officer, since 2015CN¥635,100
- Mr. Feimin JinVice President, Director of Production, since 2016CN¥678,400
- Mr. Qiang GaoDeputy General Manager, Director, since 2015CN¥779,500
- Ms. Weihong ShenSecretary of the BoardCN¥681,000
- Mr. Xiaodan GuDirector
- Ms. Ying XuDirector
- Mr. Yong HuangIndependent Director
- Ms. Yuanyuan LiIndependent Director
- Ms. Rui WangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shanghai Haoyuan Chemexpress employs 3,368 full-time employees in Health Care sector.
- Molecular building blocks and tool compounds are applied in all drug discovery stages.
- APIs and intermediates are key products distributed domestically and overseas.
Weaknesses
- Headquartered in Shanghai, Shanghai limits global market reach.
- IPO on 8 June 2021 restricts long-term financial planning.
- Limited to Life Sciences Tools & Services industry without diversification.
Opportunities
- Expanding domestic market for molecular building blocks in China.
- Growing overseas demand for APIs and intermediates in Europe.
- Increasing CRO services in Health Care sector globally.
Threats
- Competition from domestic Life Sciences Tools & Services firms.
- Regulatory changes in Health Care industry affecting APIs.
- Economic downturns impacting global pharmaceutical markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.